Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Pfizer joins Minnesota and Company to discuss how to protect yourself by scheduling your vaccines to prevent serious consequences.

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

One Zelienople child survived a serious health scare after coming down with respiratory syncytial virus in late January. The ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...